Prelude Therapeutics PRLD Cash Flow Statement (2019-2026)

NASDAQ PRLD
$5.43 +0.18 (+3.43%)
As of: Sep 4, 2026 · 12:48 PM EDT
Reported Financials

Prelude Therapeutics Quarterly Cash Flow Statement

Periods 28 quarters
Latest Jun 2026

Prelude Therapeutics reported cash from operations of -$15.57M and free cash flow of -$15.60M for the quarter ended Jun 2026, up 40.3% year over year. This cash flow statement covers 28 quarters of results from Sep 2019 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-30.84M-33.01M-30.29M-29.46M-30.41M-33.38M-29.11M-32.40M-33.38M-37.38M-34.34M-37.16M-34.38M-33.83M-34.61M-32.19M-20.42M-17.35M-14.18M-15.45M
Share-based CompensationStock Comp.
8.09M5.78M8.54M8.92M9.20M5.84M11.87M12.08M12.13M5.91M14.74M15.18M15.04M3.77M16.64M16.48M15.50M1.84M17.69M18.21M
Cash from OperationsCash from Ops.
-21.77M-25.70M-21.89M-18.47M-20.44M-22.93M-30.13M-27.67M-25.68M-23.58M-31.79M-23.06M-27.30M-20.74M-34.23M-26.07M-19.11M23.12M-21.68M-15.57M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
0.36M-2.29M-0.75M-1.04M-0.99M0.18M0.45M0.43M1.53M1.07M1.54M1.33M0.81M0.95M0.38M0.38M0.38M0.38M0.39M0.39M
Depreciation & Amortization (CF)Dep. & Amort.
0.27M0.29M0.31M0.32M0.34M0.36M0.28M0.28M0.28M0.33M0.43M0.45M0.41M0.49M0.43M0.43M0.42M0.42M0.39M0.35M
Change in Working Capital
Change in Account PayablesChange Payables
4.51M-3.93M0.00M-0.84M3.73M-3.24M0.37M-1.71M-0.47M-0.47M0.63M1.08M-0.21M1.81M-1.91M-0.85M-2.43M1.27M-1.88M-0.15M
Change in Accured ExpensesChange Accured Exp.
0.46M2.86M-0.40M0.90M3.17M3.17M-1.90M-2.59M2.62M4.39M-5.69M1.23M2.09M1.57M-3.97M1.87M-0.37M-0.52M-6.60M1.92M
Investing Activities
Capital ExpendituresCapex
0.66M0.30M0.95M0.76M0.92M0.39M0.81M0.98M0.59M1.13M0.29M0.36M0.06M0.05M0.05M0.02M0.03M
Change in Acquisitions & DivestmentsChange Acquisitions
42.50M45.08M81.36M35.00M26.00M46.50M49.75M68.25M37.00M34.36M42.79M29.50M71.70M36.20M40.09M6.40M8.50M24.46M
Cash from Investing ActivitiesCash from Investing
-260.63M-1.80M0.15M58.58M21.61M1.35M18.00M-75.43M15.04M7.74M31.22M26.12M10.73M22.12M62.19M11.52M40.09M-60.34M8.50M-65.50M
Financing Activities
Other financing activitiesOther financing
0.71M1.99M0.15M0.15M0.06M0.07M0.03M0.32M0.29M0.00M0.25M0.12M0.09M0.06M0.03M0.09M
Cash from Financing ActivitiesCash from Financing
0.71M1.95M41.55M-41.04M0.15M0.15M-0.27M111.34M0.09M25.24M-0.01M0.06M-0.13M-0.03M-0.16M0.04M-0.01M24.94M-0.31M85.82M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
2.60M1.65M3.88M2.69M3.24M3.07M3.92M3.33M3.79M3.57M
Net Equity Issued and RepurchasedNet Equity Issued
Additional items
Change in Cash
-281.69M-25.55M19.81M-0.93M1.32M-21.42M-12.40M8.24M-10.55M9.39M-0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M-12.28M-13.50M4.74M
Free Cash FlowFCF
-22.43M-26.00M-22.85M-19.23M-21.36M-23.32M-30.94M-28.65M-26.27M-24.71M-32.08M-23.42M-27.36M-20.80M-34.28M-26.09M-19.11M23.12M-21.68M-15.60M
Net Cash FlowNCF
-281.69M-25.55M19.81M-0.93M1.32M-21.42M-12.40M8.24M-10.55M9.39M-0.58M3.12M-16.69M1.34M27.80M-14.52M20.97M-12.28M-13.50M4.74M